Breath Diagnostics, Inc. Achieves FDA Breakthrough Device Status for OneBreath™ Platform for Pneumonia Risk Assessment

Breath Diagnostics, Inc. Achieves Breakthrough Device Designation for OneBreath™ Platform

Breath Diagnostics, Inc., based in Louisville, Kentucky, is making waves in the field of breath-based molecular diagnostics with its recent accomplishment: the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its innovative platform, OneBreath™. This significant recognition reflects the potential of OneBreath™ to revolutionize pre-operative assessments by helping to identify patients at heightened risk of developing pneumonia following elective cardiac surgeries.

The Significance of OneBreath™

The Breakthrough Device Designation is reserved for medical devices that exhibit the potential to provide improved treatment or diagnosis of serious or life-threatening conditions. OneBreath™ operates as an in vitro diagnostic tool that qualitatively assesses exhaled volatile organic compounds (VOCs) derived from a patient’s breath. This analysis aims to enhance perioperative risk stratification and management, ultimately improving patient outcomes.

CEO Ivan Lo expressed optimism about this milestone, emphasizing that OneBreath™ represents the cutting edge of breath-based diagnostics. The technology stands out in a largely sensor-driven landscape, as it utilizes liquid chromatography-mass spectrometry (LC-MS) to perform a direct and precise analysis of specific chemical compounds in breath. This allows for high analytical specificity and supports better detection of risks associated with post-operative pneumonia.

How OneBreath™ Works

Utilizing a single-breath sampling method, OneBreath™ requires the patient to exhale once, after which the VOCs are analyzed through a rapid LC-MS process. Impressively, this workflow takes roughly ten minutes and is designed to seamlessly integrate into existing clinical protocols without adding additional burdens on healthcare teams or patients.

As noted by Lo, breath analysis provides a swift and non-invasive readout of biological and metabolic processes. This characteristic can significantly increase patient compliance for testing when compared to more invasive methods, like blood draws. The information gained from breath samples can assist doctors in monitoring inflammatory responses and metabolic activities linked to various health risks, including pneumonia.

Future Aspirations and Regulatory Pathway

Breath Diagnostics, Inc. plans to leverage this Breakthrough Device Designation to work closely with the FDA as they continue to develop OneBreath™. Although the designation is promising, it is vital to note that it does not guarantee expedited approval or commercial availability. Clinical evaluations will still be essential to determine safety and effectiveness before OneBreath™ can be widely utilized.

The aim is not to solely utilize OneBreath™ for pneumonia diagnosis but rather to position it as a versatile platform that could support various clinical applications moving forward. This reflects the ambition of the company to address significant unmet clinical needs through its innovative technology.

In conclusion, as Breath Diagnostics, Inc. forges ahead, there is hope that OneBreath™ will not only bring quicker risk assessments to cardiac surgery patients but will also pave the way for broader applications in non-invasive diagnostics. As the healthcare landscape continues to evolve, breath analysis could play an increasingly crucial role in patient care, diagnosis, and monitoring, creating a healthier future for all.

For more detailed updates or to learn more about their technology, visit breathdiagnostics.com or follow Breath Diagnostics, Inc. on LinkedIn and Twitter.